MANE

Veradermics, Inc Health Care Pharmaceutical Preparations Russell 3000

$139.69Close $104.7MMarket cap $37.03 – $143.8552-week range Nov 10, 2026Next report

Highlights

Strengths

Accumulation up-day volume 1.6× down-day volume over 50 sessions

Cautions

Results soon Nov 10, 2026, in 9 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 11, 2026

Off 12-month high 3%

1wk 0.7% price change

1mo 15.2% price change

12-month return 270% total, dividends included

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B — price / book

Earnings yield 87.2% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE — return on equity

Free cash margin — -$71.6M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 5.6% $7.84 a day · 2×ATR $124.01

RS — vs the universe

Trend — trend template

Relative volume 0.6× vs 50-day average

Up/down volume 1.62 50 sessions

Implied move — no option chain · report Nov 10, 2026

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Liabilities exceed assets Shareholders' equity is negative at -$121.0M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.

Last reported Aug 11, 2026

Last shock Jul 16, 2026-14% in one session2.0× volumeon an SEC filing+32% since

Financials

2 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$70.0M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$71.6M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 749.76k +1.7% since FY2024

	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Operating income	-$26.8M	-$72.3M
Net income	-$26.5M	-$70.0M
Earnings per share	-$35.94	-$93.95
Free cash flow	-$23.7M	-$71.6M
Cash	$53.1M	$21.8M
Shareholders' equity	-$48.5M	-$121.0M
Shares outstanding	736.93k	749.76k

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 11, 2026	Quarterly ↗	Jun 30, 2026	42d
May 12, 2026	Quarterly ↗	Mar 31, 2026	42d
Mar 30, 2026	Annual ↗	Dec 31, 2025	89d

Current reports

Filed	Disclosed
Oct 19, 2026	Regulation FD · Other events ↗
Aug 11, 2026	Results ↗
Jul 15, 2026	Regulation FD · Other events ↗
May 12, 2026	Results ↗
May 1, 2026	Material agreement · Unregistered share sale ↗
Apr 27, 2026	Results ↗
Apr 27, 2026	Regulation FD · Other events ↗
Mar 30, 2026	Results ↗
Feb 5, 2026	Charter or bylaws ↗